Newsroom

Industry News

27 Mar

SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace

SurePure, Inc. (OTCQB: SURP), a global leader in liquid photopurification, announced today that the Company has completed the verification process and received approval for the continued trading of SurePure (“SURP”) securities on OTCQB, an electronic quote and trade execution venture marketplace for entrepreneurial and development stage companies. On March...

Read more

25 Mar

TapImmune to Present at the Maidstone Life Sciences “Cancer Immunotherapy: A Long-Awaited Reality” on Thursday March 26, 2015

TapImmune Inc. (TPIV), a clinical stage immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today that Dr. Glynn Wilson, Chairman & CEO  will present a corporate update at the Fifth Annual: “Cancer Immunotherapy: A Long-Awaited Reality” conference at the New...

Read more

25 Mar

Arch Therapeutics Announces Favorable Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Cellulose-Based Hemostatic Agent

Data Shows Faster Time to Hemostasis for AC5(TM) Versus Marketed Product Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced that...

Read more

25 Mar

CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia

CymaBay Therapeutics, Inc. (CBAY) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for MBX-8025 as a treatment for homozygous familial hypercholesterolemia (HoFH). MBX-8025 is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist being evaluated in high unmet need and...

Read more

24 Mar

Amedica Clinical Study Results

A DISRUPTIVE ARTHRODESIS TECHNOLOGY THAT DOES NOT REQUIRE AUTOGRAFT BONE 12 MONTH RESULTS FROM THE CASCADE CLINICAL STUDY Do you know that there is a synthetic arthrodesis device that matches autograft, the gold Standard, in fusion performance? You’ll discover more surprising results when the principal investigator of the CASCADE...

Read more

24 Mar

Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine

Enteric-Coated Buprenorphine Product Candidates (BuTab, REL-1028) to be Compared with Marketed Intravenous and Sublingual Formulations Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it has received a No Objection Letter (“NOL”) from Health Canada to conduct the first...

Read more

24 Mar

Soligenix Announces Recent Accomplishments and Year-End 2014 Financial Results

Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today recent accomplishments and financial results for the year ended December 31, 2014. Christopher J. Schaber, PhD, President and Chief Executive Officer...

Read more

24 Mar

CymaBay Therapeutics Appoints Robert J. Wills, Ph.D. to Board of Directors

CymaBay Therapeutics, Inc. (CBAY) today announced the appointment of Robert J. Wills, Ph.D., to the Company’s Board of Directors. “Rob brings to CymaBay over 35 years of pharmaceutical experience, including preclinical and clinical research and development, business development and strategic partnering,” said Harold Van Wart, President and Chief Executive Officer...

Read more

Page 1 of 5712345...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets